Temperature-sensitive liquid embolic agent transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for BCLC Stage B/C hepatocellular carcinoma: a multicenter real-world study and spatial transcriptomics profiling (CHANCE 2515)

医学 肝细胞癌 索拉非尼 放射科 栓塞 阶段(地层学) 肝癌 血栓形成 总体生存率 肿瘤科 内科学 实体瘤疗效评价标准 胃肠病学 门静脉血栓形成 临床试验 转录组 核医学 多元分析 肿瘤微环境 队列 癌 成纤维细胞活化蛋白 放射基因组学 存活率 外科肿瘤学
作者
Qingyun Xie,Ying Yang,Sinan Xie,Xiaojuan Yang,Fengwei Gao,Weili Qi,Hu Liu,Yuanjun Liu,Jiran Deng,Xianguo Liu,Yi Zhou,Xin Zhao,Kangyi Jiang,Tianyang Mao,Xiuyong Liao,Ruihong Dai,Yinghao Lyu,Yunshi Cai,Kunlin Xie,Hong Wu
出处
期刊:Signal Transduction and Targeted Therapy [Springer Nature]
卷期号:11 (1): 329-
标识
DOI:10.1038/s41392-026-02953-5
摘要

Transarterial chemoembolization (TACE) remains a cornerstone therapy for intermediate-to-advanced hepatocellular carcinoma (HCC); however, the optimal embolic platform remains uncertain. This multicenter, retrospective, real-world study (Clinical trial registration number: ChiCTR2500113198) conducted across China compared a novel temperature-sensitive liquid embolic agent, TempSLE-TACE (T-TACE), with conventional drug-eluting bead TACE (D-TACE) in 328 patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C HCC. Following inverse probability of treatment weighting (IPTW), T-TACE achieved significantly superior objective response rates (ORRs) compared with D-TACE according to both RECIST 1.1 criteria (54.11% vs. 27.78%, P < 0.001) and mRECIST criteria (73.56% vs. 54.93%, P = 0.002). T-TACE was additionally associated with significantly prolonged progression-free survival (median PFS: 12.0 vs. 9.0 months; HR = 0.67, P = 0.001) and overall survival (median OS, 24.0 vs. 15.0 months; HR = 0.49, P < 0.001). Moreover, T-TACE demonstrated a favorable safety profile, with lower incidences of hepatic and gastrointestinal toxicities, including any-grade alanine aminotransferase elevation and hyperbilirubinemia. Subgroup analyses further demonstrated consistent OS, PFS, and ORR benefits across major clinical subgroups, with effect sizes remaining significantly favorable in high-risk populations, including advanced portal vein tumor thrombosis type Vp4, baseline AFP > 1000 ng/mL, and PIVKA-II > 2000 mAU/mL. Exploratory histo-molecular and spatial transcriptomic analyses suggested that T-TACE may promote immune microenvironment remodeling through enhanced Th17-cell infiltration and CD8⁺ T-cell activation, whereas incomplete embolization after D-TACE was more frequently associated with residual intermediate-state tumor cells and an immunosuppressive microenvironment. Collectively, these findings provide preliminary evidence supporting T-TACE as a promising real-world therapeutic strategy for intermediate-to-advanced HCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ding发布了新的文献求助30
刚刚
Metx完成签到 ,获得积分10
刚刚
饼大王发布了新的文献求助10
刚刚
1秒前
ohh完成签到 ,获得积分10
2秒前
无极微光的应助被吕大本事采纳,获得20
3秒前
搜集达人的应助被这题不讲采纳,获得10
4秒前
乌贼爱吃完成签到,获得积分10
5秒前
科研通AI65的应助被linn采纳,获得10
7秒前
9秒前
爆米花的应助被DW采纳,获得10
10秒前
风中的眼神完成签到,获得积分10
10秒前
10秒前
10秒前
maguodrgon发布了新的文献求助10
11秒前
12秒前
13秒前
14秒前
15秒前
猪猪侠在读研完成签到,获得积分10
15秒前
聪明笨蛋发布了新的文献求助10
15秒前
倩倩发布了新的文献求助10
16秒前
Xiao发布了新的文献求助10
18秒前
希望天下0贩的0的应助被Co采纳,获得30
19秒前
xixi发布了新的文献求助10
19秒前
20秒前
FashionBoy的应助被伶俐的不评采纳,获得10
20秒前
Orange的应助被留无影采纳,获得30
20秒前
烦人糕糕完成签到,获得积分10
20秒前
无花果的应助被伶俐的不评采纳,获得10
20秒前
秋风的应助被伶俐的不评采纳,获得10
20秒前
共享精神的应助被AA采纳,获得10
21秒前
21秒前
21秒前
orixero的应助被伶俐的不评采纳,获得10
21秒前
Nole的应助被伶俐的不评采纳,获得10
21秒前
充电宝的应助被伶俐的不评采纳,获得10
21秒前
wanci的应助被伶俐的不评采纳,获得10
21秒前
斯文败类的应助被伶俐的不评采纳,获得10
22秒前
刘亚梅完成签到 ,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188295
求助须知:如何正确求助?哪些是违规求助? 9576112
关于积分的说明 21845392
捐赠科研通 7786320
什么是DOI,文献DOI怎么找? 3435276
关于科研通互助平台的介绍 2559581
邀请新用户注册赠送积分活动 2482182